663 related articles for article (PubMed ID: 28285592)
1. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Remon J; Besse B; Soria JC
BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592
[TBL] [Abstract][Full Text] [Related]
2. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
Decatris MP; O'Byrne KJ
Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
6. [Immune checkpoint inhibitors in lung cancer].
Koleczko S; Wolf J
Internist (Berl); 2020 Jul; 61(7):676-681. PubMed ID: 32462250
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M; Schouten RD; De Gooijer CJ; Baas P
Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Fabre E; Pécuchet N; Cadranel J
Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
[TBL] [Abstract][Full Text] [Related]
9. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
10. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
11. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Domagała-Kulawik J
Adv Respir Med; 2018; 86(3):. PubMed ID: 29960281
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
16. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
Chen R; Tao Y; Xu X; Shan L; Jiang H; Yin Q; Pei L; Cai F; Ma L; Yu Y
Discov Med; 2018 Oct; 26(143):155-166. PubMed ID: 30586539
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Tsai FP; Wu TW
Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
